Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Pacific Edge Limited ( (PFGTF) ).
Pacific Edge Limited reported a resilient financial performance for the fiscal year ending March 2025, despite challenges with Medicare coverage. The company announced a NZ$20 million equity raising to capitalize on clinical and commercial milestones and aims to regain Medicare coverage for its tests. Operating revenue decreased by 8.6% to $21.8 million due to Medicare uncertainty, and total laboratory throughput of Cxbladder tests fell by 11.5%. Despite these challenges, the company achieved significant strategic progress, including the inclusion of Cxbladder Triage in the American Urological Association guidelines with a ‘Grade A’ evidence rating. The company is positioned for revenue growth in the US with a draft Medicare price set for Cxbladder Triage Plus, and it is advancing the commercialization of its tests with a focus on non-Medicare revenue streams.
More about Pacific Edge Limited
Pacific Edge Limited is a cancer diagnostics company specializing in non-invasive bladder cancer diagnostics. The company is known for its Cxbladder tests and focuses on regaining Medicare coverage while expanding in non-Medicare channels.
For an in-depth examination of PFGTF stock, go to TipRanks’ Stock Analysis page.